Genetic subtypes of JMML
I. Somatic PTPN11 mutation |
• Rapidly fatal without allogeneic HSCT |
• High probability of relapse |
• Frequent acquisition of NF1 haploinsufficiency |
II. Somatic NRAS mutation |
• Heterogeneous subtype |
• Rapid progress with high relapse rate after HSCT, typically in older children with high levels of HbF |
• Indolent course with spontaneous regression, typically in infants or in cases with G12S mutation |
III. Somatic KRAS mutation |
• Mostly infants |
• Frequent association with monosomy 7 |
• Aggressive at presentation but low risk of relapse after allogeneic HSCT |
IV. JMML in children with NF1 |
• Older age at diagnosis |
• Higher platelet count |
• Higher percentage of BM blasts |
• Fatal without allogeneic HSCT |
V. JMML in children with germline CBL mutation |
• Loss of CBL heterozygosity in hematopoietic cells |
• Absence of concomitant mutations |
• Value of allogeneic HSCT uncertain |
• Frequent occurrence of mixed chimerism after allogeneic HSCT |
I. Somatic PTPN11 mutation |
• Rapidly fatal without allogeneic HSCT |
• High probability of relapse |
• Frequent acquisition of NF1 haploinsufficiency |
II. Somatic NRAS mutation |
• Heterogeneous subtype |
• Rapid progress with high relapse rate after HSCT, typically in older children with high levels of HbF |
• Indolent course with spontaneous regression, typically in infants or in cases with G12S mutation |
III. Somatic KRAS mutation |
• Mostly infants |
• Frequent association with monosomy 7 |
• Aggressive at presentation but low risk of relapse after allogeneic HSCT |
IV. JMML in children with NF1 |
• Older age at diagnosis |
• Higher platelet count |
• Higher percentage of BM blasts |
• Fatal without allogeneic HSCT |
V. JMML in children with germline CBL mutation |
• Loss of CBL heterozygosity in hematopoietic cells |
• Absence of concomitant mutations |
• Value of allogeneic HSCT uncertain |
• Frequent occurrence of mixed chimerism after allogeneic HSCT |